Glyburide
As of the edition of 20 October 2026, Glyburide is a small molecule: marketed, first approved in 1982 (CH); acts on ABCC8 and KCNJ11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Diabeta
- First approved
- 24 November 1982 (CH)
- Approvals on record
- 20 in 5 regions
- Holder of the most recent approval
- Sanofi; 6 holders in all
- Registered trials
- 63, 11 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Nervous system; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Glyburide.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 5 | 0 | 0 |
| Phase 1 | 16 | 13 | 2 | 1 |
| Phase 2 | 11 | 6 | 1 | 3 |
| Phase 3 | 15 | 10 | 0 | 5 |
| Phase 4 | 11 | 4 | 1 | 2 |
| All trials | 63 |